| Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke: does everyone need it? | |
| | |
MedLine Citation:
|
PMID: 15331797 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: Blood pressure (BP) control is considered essential in patients treated with tissue plasminogen activator (tPA) for ischemic stroke, and it is recommended that BP be monitored every 15 minutes to 1 hour for 24 hours in these patients. We postulated that patients whose BP is not initially elevated are unlikely to have elevated BP later and, therefore, may not need prolonged BP monitoring. METHODS: We performed a retrospective chart review of patients treated with intravenous tPA for ischemic stroke over a 3-year period. Patients with incomplete records were excluded. RESULTS: Seventy-nine patients (35 male, age 68.8+/-14.3 years) were studied. Before tPA treatment, 16 patients (20%) had hypertension (systolic BP > or =185 or diastolic BP > or =110 mm Hg). All 16 patients had subsequent hypertension over the next 24 hours. Of the remaining 63, 27 patients (43%) had hypertension (systolic BP > or =180 or diastolic BP > or =105 mm Hg) within the first 6 hours. An additional 4 had minor transient systolic elevations (< or =182 mm Hg) after 6 hours that normalized without treatment. Neurological worsening, seen in 13 patients (17%), was not associated with the presence of hypertension (initial or subsequent). CONCLUSIONS: In patients receiving tPA for stroke, absence of hypertension at presentation does not preclude subsequent increase in blood pressure. However, if blood pressure is not elevated during the first 6 hours, subsequent hypertension over the next 18 hours is unlikely. This study is small and retrospective, and needs to be repeated in a larger prospective cohort. However, our results provide preliminary evidence to suggest that where resources are scarce, these patients may be discharged from the intensive care unit earlier than the recommended 24 hours, provided that they are not at high risk for neurological deterioration. |
| | |
Authors:
|
Venkatesh Aiyagari; Arunodaya Gujjar; Allyson R Zazulia; Michael N Diringer |
Related Documents
:
|
7058457 - The pathological basis of end-stage renal disease in blacks. 600967 - Minoxidil in refractory hypertension: benefits, risks. 7627247 - Is there a relationship between obesity and intracranial hypertension? 273077 - Diagnosis of pheochromocytoma during treatment of a mandibular fracture: report of case. 12639217 - Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients w... 10639527 - Relation of sputum inflammatory markers to symptoms and lung function changes in copd e... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. Date: 2004-08-26 |
Journal Detail:
|
Title: Stroke; a journal of cerebral circulation Volume: 35 ISSN: 1524-4628 ISO Abbreviation: Stroke Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-09-24 Completed Date: 2005-03-22 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0235266 Medline TA: Stroke Country: United States |
Other Details:
|
Languages: eng Pagination: 2326-30 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660 S. Euclid Avenue, St. Louis, MO 63110, USA. aiyagariv@neuro.wustl.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Blood Pressure* Blood Pressure Determination* Female Fibrinolytic Agents / administration & dosage, therapeutic use* Humans Infusions, Intravenous Male Middle Aged Retrospective Studies Stroke / drug therapy*, physiopathology Thrombolytic Therapy* Tissue Plasminogen Activator / administration & dosage, therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
1K23NS044885-01/NS/NINDS NIH HHS; 2 P01 NS035966-06/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation pat...
Next Document: Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decli...